NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Show more

Location: 9000 Virginia Manor Road, Beltsville, MD, 20705, United States | Website: https://www.nextcure.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

11.45M

52 Wk Range

$2.69 - $21.84

Previous Close

$4.90

Open

$4.82

Volume

27,648

Day Range

$4.76 - $4.93

Enterprise Value

-37.11M

Cash

55.86M

Avg Qtr Burn

-10.3M

Insider Ownership

8.91%

Institutional Own.

48.29%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NC410 (LAIR-2 fusion)+ pembrolizumab Details Cancer, Ovarian cancer, Colorectal cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LNCB74 (B7-H4 ADC) Details Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NC525 (LAIR-1 mAb) Details Solid tumor/s, Cancer, Acute myeloid leukemia	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NC318 (S15) Details Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NC318 (S15) + pembrolizumab Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NC762 (B7-H4 mAb) Details Cancer, Solid tumor/s, Lung cancer, Ovarian cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.